The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights

Frontiers in Immunology 2026 Open access

Read full text
Authors: Lifeng Ge, Tianhao Xu, Xi Gu, Xuekang Pan, Tian Gao, Huigen Lu
DOI: 10.3389/fimmu.2026.1790067
Cited by: 2
References: 12

Abstract

Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5-year overall survival (OS) is

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Cancer Genomics and Diagnostics CAR-T cell therapy research

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
17
Pages
1790067–1790067
Publication date
10 March 2026
Language
EN